Oct 31Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024
Oct 17Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
Sep 3Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024
Oct 31Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024
Sep 3Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024
Aug 6Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update
